A-Labs Capital II Corp.

As of June 30, 2026, A-Labs Capital II Corp. carries a market capitalization of 621,032.00, placing it among publicly traded companies globally. Its enterprise value stands at 697,758.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, A-Labs Capital II Corp. has 7.76M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, A-Labs Capital II Corp. maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -66.58, indicating conservative leverage, while an interest coverage ratio of -67.34 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -480.23, reflecting losses generated across the asset base.

As of the close on October 22, 2026, A-Labs Capital II Corp.'s stock has gained approximately 9.09% over the past 52 weeks.

Over the twelve months ended June 30, 2026, A-Labs Capital II Corp. generated - - in revenue and converted that into -67,977.00 in net income, yielding earnings per share of -0.02. EBITDA reached -72,325.00, while operating income came in at -72,325.00.

As of June 30, 2026, A-Labs Capital II Corp. holds 26,649.00 in cash and equivalents against 103,375.00 in total debt, resulting in a net debt position of 76,726.00. Total book value stands at -155,275.00, with working capital of -155,275.00 providing operational flexibility.

As of June 30, 2026, A-Labs Capital II Corp. has an Altman Z-Score of -46.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.